Global Biosimilars and Follow-On Biologics Market 2017-2027

LONDON, July 5, 2017 /PRNewswire/ -- Report Details
The global biosimilars and follow-on biologics market is expected to grow at a CAGR of 38.8% in the first half of the forecast period and CAGR of 11.3% in the second half of the forecast period. The market is estimated at $5.31bn in 2016 and $41.07bn in 2027.

Download the full report: https://www.reportbuyer.com/product/4974730/

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 318-page report you will receive 128 tables and 68 figures – all unavailable elsewhere.
The 318-page report provides clear detailed insight into the global biosimilars and follow-on biologics market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
• Global Biosimilars and Follow-on Biologics Market forecasts from 2017-2027
• Along with revenue prediction for the overall world market for biosimilars, our investigation shows forecasts to 2027 for 8 individual therapeutic submarkets:
- Monoclonal antibodies (mAbs)
- Fusion proteins
- Insulin
- Erythropoietin (EPO)
- Granulocyte colony-stimulating factor (G-CSF)
- Interferons
- Growth hormones
- Fertility hormones

• This report also shows revenue to 2027 for 12 individual submarkets within the above segments:
- Rituximab, infliximab, trastuzumab, adalimumab and bevacizumab
- Human insulin, insulin analogues, insulin glargine and insulin lispro
- Interferon alfa and interferon beta
- Etanercept

• Our analyses show individual revenue forecasts to 2027 for 12 national markets:
- US
- Japan
- Germany, France, UK, Italy and Spain
- China, India, South Korea, Russia and Brazil

• Our study discusses pressures, opportunities and other events affecting the biosimilars industry and market from 2016, including these influences:
- Strategies for developing biosimilars – needs, demand, challenges and opportunities
- Guidelines from regulators (FDA, EMA and others)
- Patent challenges and data exclusivity for biopharmaceuticals
- Needs and opportunities in developing biosimilar mAbs, including rising incidence of cancers and increasing demand for lower-cost biologicals
Download the full report: https://www.reportbuyer.com/product/4974730/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-biosimilars-and-follow-on-biologics-market-2017-2027-300483685.html

SOURCE ReportBuyer